Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AGO-OVAR 2.21: PLD vs Gemcitabine with Bevacizumab in Recurrent Ovarian Cancer
NCT01837251Phase 3Completed
- Sponsor
- AGO Research
- Start
- May 2013
- Primary completion
- Jan 2021
- Modality
- DNA Intercalators/Alkylators
- Countries
- 6
01
Overview
A Phase 3 trial of doxorubicin in ovarian cancer, sponsored by AGO Research. Started May 2013; status: completed.
02
Drugs
doxorubicin
03
Conditions
ovarian cancer
Beyond the preview
Go deeper on NCT01837251.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01837251.